Off-Label Atropine and Orthokeratology for a Child: Consent, Assent, and Advertising

For a 9-year-old, the legal consent comes from a parent or guardian, but the child's assent should also be sought because treatment depends on cooperation, especially with drops and overnight lens wear. The consent discussion should cover the diagnosis and prognosis, including that myopia is common and progression varies. It should explain that atropine 0.05% is being used off-label, what FDA approval means, and that compounded atropine is not FDA-approved for myopia control. The discussion should describe the evidence and its limits, the expected benefits, and the alternatives: single-vision glasses, soft multifocal contact lenses, increased outdoor time, observation, and no treatment. Risks should include photophobia, near blur, allergic reaction, punctal occlusion, and the need for sunglasses; orthokeratology risks include discomfort, corneal staining, microbial keratitis, and cost. The practice should explain the monitoring schedule, the possibility of discontinuing one treatment if adverse effects occur, and that no guarantee can be made. Starting both treatments simultaneously makes it harder to attribute side effects, so a sequential trial may be preferable. The consent conversation and the child's response should be documented in the chart, not reduced to 'discussed.'

The child's refusal should not be physically overridden or dismissed. At 9 years old, the child cannot give legal consent, but fear and inability to cooperate are clinically relevant. The optometrist should explore the reason for refusal, explain the drops and lens handling in child-friendly terms, demonstrate the procedure, and offer choices such as which eye is first or whether a parent administers the drop. If the child remains distressed, the optometrist should consider delaying orthokeratology, starting with glasses or another alternative, or using a sequential trial of atropine only after the child is more comfortable. The parent should be told that forcing treatment may harm trust and adherence. The chart should record the child's statements, the attempts to address fear, the parent's decision, and the revised plan. If the parent insists, the optometrist should document the assent discussion, the child's ongoing reluctance, and the safety plan. Consent is ongoing, so the optometrist should reassess at each visit and stop treatment if the child cannot tolerate it. The goal is a defensible, patient-centered process, not a signed form alone.

The advertisement is misleading in at least two ways. First, compounded atropine 0.05% is not FDA-approved for myopia control, so calling the treatment 'FDA-approved' is false or at least confusing. Second, 'stops progression-guaranteed' overstates the evidence and promises a result that cannot be guaranteed. Indiana Board of Optometry advertising rules prohibit false, deceptive, or misleading statements, and the FTC Act separately prohibits deceptive advertising. The phrase 'myopia control' may be used if it is accurately described as slowing progression in some children, not curing or stopping it. The social-media before-and-after graphs and the 12-year-old's testimonial require a HIPAA authorization signed by the parent or guardian, and the practice should use minimum necessary information. Even with authorization, a testimonial from a minor should be scrutinized for undue influence. The practice should remove the guarantee and 'FDA-approved' claim, revise the consent form, and document the actual discussion. The optometrist should also ensure that the website and social media identify the practice accurately and do not imply specialization that the optometrist does not hold.